These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29561294)

  • 21. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995.
    Broers B; Junet C; Bourquin M; Déglon JJ; Perrin L; Hirschel B
    AIDS; 1998 Oct; 12(15):2059-66. PubMed ID: 9814875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual sexual and drug-related predictors of hepatitis C incidence among sex workers in a Canadian setting: gaps and opportunities for scale-up of hepatitis C virus prevention, treatment, and care.
    Goldenberg SM; Montaner J; Braschel M; Socias E; Guillemi S; Shannon K
    Int J Infect Dis; 2017 Feb; 55():31-37. PubMed ID: 28027990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study.
    Jauffret-Roustide M; Emmanuelli J; Quaglia M; Barin F; Arduin P; Laporte A; Desenclos JC
    Subst Use Misuse; 2006; 41(10-12):1603-21. PubMed ID: 17002994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART.
    Lumbreras B; Jarrín I; del Amo J; Pérez-Hoyos S; Muga R; García-de la Hera M; Ferreros I; Sanvisens A; Hurtado I; Hernández-Aguado I
    AIDS; 2006 Jan; 20(1):111-6. PubMed ID: 16327326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
    Wandeler G; Gsponer T; Bregenzer A; Günthard HF; Clerc O; Calmy A; Stöckle M; Bernasconi E; Furrer H; Rauch A;
    Clin Infect Dis; 2012 Nov; 55(10):1408-16. PubMed ID: 22893583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md.
    Nelson KE; Vlahov D; Solomon L; Cohn S; Muñoz A
    Arch Intern Med; 1995 Jun; 155(12):1305-11. PubMed ID: 7778962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.
    van den Berg CH; Smit C; Bakker M; Geskus RB; Berkhout B; Jurriaans S; Coutinho RA; Wolthers KC; Prins M
    Eur J Epidemiol; 2007; 22(3):183-93. PubMed ID: 17334821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion.
    Wilton J; Wong S; Purssell R; Abdia Y; Chong M; Karim ME; MacInnes A; Bartlett SR; Balshaw RF; Gomes T; Yu A; Alvarez M; Dart RC; Krajden M; Buxton JA; Janjua NZ
    JAMA Netw Open; 2022 Jan; 5(1):e2143050. PubMed ID: 35019983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France.
    Lucidarme D; Bruandet A; Ilef D; Harbonnier J; Jacob C; Decoster A; Delamare C; Cyran C; Van Hoenacker AF; Frémaux D; Josse P; Emmanuelli J; Le Strat Y; Desenclos JC; Filoche B
    Epidemiol Infect; 2004 Aug; 132(4):699-708. PubMed ID: 15310172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.
    Elliott JC; Hasin DS; Stohl M; Des Jarlais DC
    AIDS Behav; 2016 Mar; 20(3):548-54. PubMed ID: 26080690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study.
    Omland LH; Jepsen P; Weis N; Christensen PB; Laursen AL; Nielsen H; Krarup H; Sørensen HT; Obel N
    J Viral Hepat; 2010 Apr; 17(4):261-8. PubMed ID: 19709359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study.
    Leprêtre A; Ba I; Lacombe K; Maynart M; Toufik A; Ndiaye O; Kane CT; Gozlan J; Tine J; Ndoye I; Raguin G; Girard PM
    J Int AIDS Soc; 2015; 18(1):19888. PubMed ID: 26004637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
    Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users.
    Spillane H; Nicholas S; Tang Z; Szumilin E; Balkan S; Pujades-Rodriguez M
    Trop Med Int Health; 2012 Oct; 17(10):1255-63. PubMed ID: 22863110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions.
    Sobrino-Vegas P; Monge Corella S; Serrano-Villar S; Gutiérrez F; Blanco JR; Santos I; del Romero J; Segura F; Portilla J; Guillén SM; del Amo J;
    PLoS One; 2014; 9(12):e116226. PubMed ID: 25549224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users.
    Levine OS; Vlahov D; Brookmeyer R; Cohn S; Nelson KE
    J Infect Dis; 1996 Mar; 173(3):579-83. PubMed ID: 8627020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.
    Mbizvo MT; Machekano R; McFarland W; Ray S; Bassett M; Latif A; Katzenstein D
    AIDS; 1996 Jul; 10(8):895-901. PubMed ID: 8828747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion.
    Grady B; van den Berg C; van der Helm J; Schinkel J; Coutinho R; Krol A; Prins M
    Clin Gastroenterol Hepatol; 2011 Sep; 9(9):786-792.e1. PubMed ID: 21699803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in southwest China.
    Ruan Y; Liang S; Zhu J; Li X; Pan SW; Liu Q; Song B; Wang Q; Xing H; Shao Y
    Sex Transm Dis; 2013 Apr; 40(4):323-8. PubMed ID: 23486498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.